dc.date.accessioned | 2020-03-11T20:32:42Z | |
dc.date.accessioned | 2022-10-18T22:54:31Z | |
dc.date.available | 2020-03-11T20:32:42Z | |
dc.date.available | 2022-10-18T22:54:31Z | |
dc.date.created | 2020-03-11T20:32:42Z | |
dc.date.issued | 2016 | |
dc.identifier | http://hdl.handle.net/10533/239807 | |
dc.identifier | 15130011 | |
dc.identifier | WOS:000367009500006 | |
dc.identifier | no scielo | |
dc.identifier | eid=2-s2.0-84952664963 | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/4471146 | |
dc.description.abstract | Current strategies for brain diseases are mostly symptomatic and noncurative. Nanotechnology has the potential to facilitate the transport of drugs across the blood-brain barrier and to enhance their pharmacokinetic profile. However, to reach clinical app | |
dc.language | eng | |
dc.relation | https://doi.org/10.2217/nnm.15.189 | |
dc.relation | 10.2217/nnm.15.189 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.rights | Atribución-NoComercial-SinDerivadas 3.0 Chile | |
dc.rights | http://creativecommons.org/licenses/by-nc-nd/3.0/cl/ | |
dc.title | Nanomedicine and nanotoxicology: the pros and cons for neurodegeneration and brain cancer | |
dc.type | Articulo | |